This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Andrews, N. Articles by Miller, E. Search for Related Content PubMed PubMed Citation Articles by Andrews, N. Articles by Miller, E.

Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England

Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ,¹ PHLS Meningococcal Reference Unit, Withington Hospital, Manchester M20 2LR, United Kingdom²

Received 1 July 2002/ Returned for modification 31 March 2003/ Accepted 4 June 2003

Meningococcal C conjugate (MCC) vaccines were licensed on the basis of serological correlates of protection without efficacy data. The original correlate of protection was established by using a serum bactericidal antibody assay (SBA) with human complement (hSBA), with titers 4 predicting protection. However, the antibody data supporting licensure were largely generated by SBA with rabbit complement (rSBA), which gives higher titers than hSBA. While rSBA titers 128 reliably predict protection, as measured by hSBA, sera with rSBA titers in the range of 8 to 64 may not have hSBA titers 4. For rSBA titers in this equivocal range, a fourfold rise pre- to postvaccination with the MCC vaccine and/or a characteristic booster response to a polysaccharide challenge was proposed as a correlate of protection. To validate this proposed rSBA correlate, age-specific efficacy estimates for MCC vaccines obtained from postlicensure surveillance in England were compared with the efficacy predicted by the percentage of individuals in these age groups with rSBA titers above different cutoffs at 4 weeks and at 7 to 9 months after vaccination with the MCC vaccine. The average time since vaccination in the cohorts in whom efficacy was measured ranged from 8 to 10 months. The rSBA cutoff of 128 was shown to significantly underestimate efficacy, with rSBA cutoffs of 4 or 8 at 4 weeks postvaccination with the MCC vaccine being the most consistent with observed efficacy. When the levels obtained 7 to 9 months postvaccination with the MCC vaccine were used, all rSBA cutoffs significantly underestimated efficacy, suggesting that continuing protection is less dependent on the SBA level at the time of exposure but is more reliant on immunologic memory.

This article has been cited by other articles:

• (2006). Inadvertent Misadministration of Meningococcal Conjugate Vaccine--United States, June-August 2005. JAMA 296: 2082-2083 [Full Text]  
• Huo, Z., Sinha, R., McNeela, E. A., Borrow, R., Giemza, R., Cosgrove, C., Heath, P. T., Mills, K. H. G., Rappuoli, R., Griffin, G. E., Lewis, D. J. M. (2005). Induction of Protective Serum Meningococcal Bactericidal and Diphtheria-Neutralizing Antibodies and Mucosal Immunoglobulin A in Volunteers by Nasal Insufflations of the Neisseria meningitidis Serogroup C Polysaccharide-CRM197 Conjugate Vaccine Mixed with Chitosan. Infect. Immun. 73: 8256-8265 [Abstract] [Full Text]  
• Borrow, R., Aaberge, I. S., Santos, G. F., Eudey, T. L., Oster, P., Glennie, A., Findlow, J., Hoiby, E. A., Rosenqvist, E., Balmer, P., Martin, D. (2005). Interlaboratory Standardization of the Measurement of Serum Bactericidal Activity by Using Human Complement against Meningococcal Serogroup B, Strain 44/76-SL, before and after Vaccination with the Norwegian MenBvac Outer Membrane Vesicle Vaccine. CVI 12: 970-976 [Abstract] [Full Text]  
• Committee on Infectious Diseases, (2005). Prevention and Control of Meningococcal Disease: Recommendations for Use of Meningococcal Vaccines in Pediatric Patients. Pediatrics 116: 496-505 [Abstract] [Full Text]  
• Al-Mazrou, Y., Khalil, M., Borrow, R., Balmer, P., Bramwell, J., Lal, G., Andrews, N., Al-Jeffri, M. (2005). Serologic Responses to ACYW135 Polysaccharide Meningococcal Vaccine in Saudi Children under 5 Years of Age. Infect. Immun. 73: 2932-2939 [Abstract] [Full Text]  
• Buttery, J. P., Riddell, A., McVernon, J., Chantler, T., Lane, L., Bowen-Morris, J., Diggle, L., Morris, R., Harnden, A., Lockhart, S., Pollard, A. J., Cartwright, K., Moxon, E. R. (2005). Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants: A Randomized Controlled Trial. JAMA 293: 1751-1758 [Abstract] [Full Text]  
• Southern, J., Deane, S., Ashton, L., Borrow, R., Goldblatt, D., Andrews, N., Balmer, P., Morris, R., Kroll, J. S., Miller, E. (2004). Effects of Prior Polysaccharide Vaccination on Magnitude, Duration, and Quality of Immune Responses to and Safety Profile of a Meningococcal Serogroup C Tetanus Toxoid Conjugate Vaccination in Adults. CVI 11: 1100-1104 [Abstract] [Full Text]  
• Welsch, J. A., Granoff, D. (2004). Naturally Acquired Passive Protective Activity against Neisseria meningitidis Group C in the Absence of Serum Bactericidal Activity. Infect. Immun. 72: 5903-5909 [Abstract] [Full Text]  
• Garcia-Ojeda, P. A., Hardy, S., Kozlowski, S., Stein, K. E., Feavers, I. M. (2004). Surface Plasmon Resonance Analysis of Antipolysaccharide Antibody Specificity: Responses to Meningococcal Group C Conjugate Vaccines and Bacteria. Infect. Immun. 72: 3451-3460 [Abstract] [Full Text]  
• Jokhdar, H., Borrow, R., Sultan, A., Adi, M., Riley, C., Fuller, E., Baxter, D. (2004). Immunologic Hyporesponsiveness to Serogroup C but Not Serogroup A following Repeated Meningococcal A/C Polysaccharide Vaccination in Saudi Arabia. CVI 11: 83-88 [Abstract] [Full Text]  
• Balmer, P., Falconer, M., McDonald, P., Andrews, N., Fuller, E., Riley, C., Kaczmarski, E., Borrow, R. (2004). Immune Response to Meningococcal Serogroup C Conjugate Vaccine in Asplenic Individuals. Infect. Immun. 72: 332-337 [Abstract] [Full Text]